Day: October 29, 2021

RALEIGH, N.C., Oct. 29, 2021 (GLOBE NEWSWIRE) — Integrated Financial Holdings, Inc. (OTCQX: IFHI) (the “Company” or “IFH”), the financial holding company for West Town Bank & Trust (“the Bank”), released its financial results for the three and nine months ended September 30, 2021. Highlights include the following:Third quarter net income of $2.9 million or $1.32 per diluted share compared to 2020 third quarter net income of $1.7 million or $0.78 per diluted share.   Provision for loan losses of $500,000 for the third quarter of 2021 compared to $125,000 for the same period in 2020. Return on average assets of 2.61%, compared to 1.84% for the third quarter of 2020. Return on average common equity of 13.6%, compared to 9.23% for the third quarter of 2020. Return on average tangible common equity (a non-GAAP financial measure)...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – October 29, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that current Chief Financial Officer David Renas will be stepping down from his position for personal reasons, effective January 5, 2022. ObsEva has retained an executive search firm to assist the Company’s Board of Directors with identifying a new Chief Financial Officer. “On behalf of the Board of Directors and Executive team, I would like to thank Dave for his contributions to the Company over the past year and wish him all the best for the future, “said Brian O’Callaghan, CEO of ObsEva. David Renas added, “It has been my pleasure working with ObsEva during this...

TORONTO, Oct. 29, 2021 (GLOBE NEWSWIRE) — (TSX: SBN; SBN.PR.A) S Split Corp. (the “Fund”) announced today that the term of the Fund is being extended automatically for an additional seven-year period beyond the November 30, 2021 termination date to November 30, 2028 as provided for in its articles of incorporation. In connection with the automatic extension of the term, holders of Class A shares and Preferred shares have a special retraction right (“Special Retraction Right”) to permit holders of such securities to retract such shares on November 30, 2021 on the terms on which such shares would have been redeemed had the term of the Fund not been extended. Retraction payments for Class A shares and Preferred shares tendered pursuant to the Special Retraction Right will be made no later than 10 business days following the retraction...

HAMILTON, Bermuda, Oct. 29, 2021 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Monday, November 1, 2021, at 8:30 a.m. Eastern Time to report its third quarter 2021 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours of the event. The conference call can be accessed by dialing (866) 614-0636 (U.S. and Canada) or (409) 231-2053 (international) using conference ID number 1699563. About KiniksaKiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients...

HENDERSON, Colo., Oct. 29, 2021 (GLOBE NEWSWIRE) — MYR Group Inc. (“MYR Group”) (NASDAQ: MYRG), a holding company of leading specialty contractors serving the electric utility infrastructure, commercial and industrial construction markets in the United States and western Canada, announced it will attend Baird’s 2021 Global Industrial Conference. MYR Group’s Chief Executive Officer, Rick Swartz, and Chief Financial Officer, Betty Johnson, will virtually meet with institutional investors during the conference on Tuesday, November 9, 2021. This event is only available to Baird’s clients. About MYR Group Inc.MYR Group is a holding company of leading specialty contractors serving the electric utility infrastructure, commercial and industrial construction markets throughout the United States and western Canada who have the experience...

 Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine kinase inhibitor (TKI) treatments1In the pivotal Phase III ASCEMBL trial, Scemblix demonstrated significant and clinically meaningful superiority in major molecular response (MMR) rate vs. Bosulif®* (bosutinib) (25% vs. 13%) at 24 weeks, and more -than -three times lower discontinuation rates due to side effects (7% vs. 25%)2,3Additional Phase I data in patients with CML with the T315I mutation supported the FDA approval for a second indication in this patient population4With a new mechanism of action known in scientific literature as a STAMP inhibitor and clinical trials across treatment lines – including in the first-line setting –,...

IRVING, Texas, Oct. 29, 2021 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela” or the “Company”) (NASDAQ:XELA), a global business process automation (“BPA”) leader across numerous industries, will host a conference call with the financial community to discuss results for the third quarter 2021 at 2:00 p.m. ET on November 5, 2021. Exela will issue a press release reporting its results before the start of the call.   Hosting the call and reviewing the results will be Ron Cogburn, Chief Executive Officer, and Shrikant Sortur, Chief Financial Officer. Following the review, there will be a question and answer session. The conference call will be broadcast live on Exela’s Investor Relations website at http://investors.exelatech.com. Third Quarter 2021 Results Webcast and Call Access InformationDate:    November 5, 2021     Time:   2:00...

New York, NY, Oct. 29, 2021 (GLOBE NEWSWIRE) —  Deep Medicine Acquisition Corp. (Nasdaq: DMAQU) (the “Company”) today announced the closing of its upsized initial public offering of 12,650,000 units at a price to the public of $10.00 per unit, which includes 1,650,000 units issued pursuant to the underwriters’ exercise of over-allotment option in full, with the offering raising gross proceeds of $126,500,000. The units commenced trading on Wednesday, October 27, 2021, on The Nasdaq Global Market (“Nasdaq”) under the symbol “DMAQU.” Each unit issued in the initial public offering consists of one share of Class A common stock and one right to receive one-tenth of one share of Class A common stock upon the consummation of the Company’s initial business combination. Once the securities comprising the units begin separate trading, the...